Novartis
European stocks flat; Novartis plunge weighs on Switzerland's SMI
Markets held steady as high energy prices and inflation fears kept investors cautious, while a failed drug trial sent Novartis shares tumbling nearly 9%, dragging the Swiss SMI down more than 1%.
European Stocks Stay Flat; Novartis Study Flop Weighs on Swiss SMI
EuroStoxx 50 flat as high oil and gas prices persist. The Swiss SMI drops 1.18% while Novartis shares fall over 9% after a failed drug trial sinks the stock.
Novartis Plunges After Failed Muscle-Disease Trial; SMI Slides 1.3%
Novartis tumbled nearly 10% after its del-desiran candidate missed a Phase III primary endpoint, erasing roughly CHF 24 billion in market value and pulling the SMI lower. Nestlé and Roche helped stem the damage.
Swiss SMI opens lower as Novartis slides over 10% on trial setbacks; Nestlé leads gains
Novartis shares fell more than 10% to CHF 112.54 after missing primary endpoints in two late‑stage studies, dragging the SMI down 1.4%. Nestlé rose 2% while copper hit a record $14,533 a tonne.
Copper Hits Record as Novartis Drops on Study Miss; SMI Expected Lower
Copper surged to an all-time high above $14,500 a tonne on supply fears, while Novartis sank 5.2% pre-market after a failed muscle-disease study. The SMI was expected to open down.
European stocks little changed ahead of ECB decision and US inflation data
European equities were little moved Monday as investors awaited the ECB decision and US inflation data; oil shares rose on Gulf tensions while the SMI fell on Novartis and Swiss Re.
SMI falls 0.8% as Novartis and Swiss Re lead losses
Switzerland's benchmark index closed at 14,279 after Novartis and Swiss Re weighed, while ABB, Kühne+Nagel and semiconductor suppliers offset some declines.
Mirabaud sees Swiss equities as global niche leaders, not just defensive
Daniele Scilingo sees Swiss stocks as global niche leaders, warns AI valuations are stretched, and points to compounders, China adaptation, pharma innovation and UBS.
Swiss SMI slides over 1%, LVMH hits six‑year low, ABB leads gains
The Swiss market index fell to 14,221 as LVMH reached its lowest level since 2018, while ABB posted the biggest rise; USD/CHF slipped to 80.89 Rappen and US exchanges stayed closed for a holiday.
Swiss equities slip as US markets close, Novartis drags index lower; USD/CHF falls
The SMI fell 1.2% to 14,221 points after Novartis lost 3.3% on a failed drug trial, while the franc edged higher to 80.89 per dollar and USD/JPY slipped to 154.07 yen.
Swiss market slides as Novartis falls on failed drug trial, dollar weakens against franc
The SMI dropped over 1% to 14,221 points, led by a 3% slide in Novartis after negative Pelacarsen news, while the U.S. dollar fell to 80.89 rappen.
Swiss SMI slides over 1% as Novartis tumbles on failed drug trial
SMI fell 1.2% to 14,221 points, led by a 4.2% drop in Novartis after its Pelacarsen trial missed; other health‑care stocks and Schindler also fell, while Kühne+Nagel and ABB posted modest gains.
Swiss equities slip as Roche, Novartis drag; ABB gains, yen hits 7‑month high
The SMI fell about 1% to 14,221 points, led by 3%‑plus losses in Novartis and Roche after a failed Pelacarsen trial. ABB rose, while the yen strengthened to 154.07 per dollar, its lowest level in seven months.
Swiss stocks rise as Roche leads; Richemont falls on luxury sector weakness
Swiss Market Index edges up 0.12% as Roche gains on licensing deal, while Richemont drops 2.4% amid broader luxury sector decline. Swiss franc strengthens to 0.9384 per euro after August inflation surprise.
Swiss stocks rise on US gains; Nestlé, Richemont drag; franc strengthens
Swiss Market Index edges up 0.2% after early 0.5% gain as Nestlé drags; Roche and Logitech lead gains. Euro falls to 0.9384 francs as Swiss inflation surprises.
US stocks rise on softer yields; Swiss franc strengthens after inflation surprise
U.S. benchmarks advance 0.4-0.6% at open as Treasury yields ease; SMI up 0.5% led by Roche and Logitech. Swiss inflation hits two-year high, lifting franc to 0.9392 per euro.
US stocks set for modest gain; SMI rises on Roche, Logitech gains; Swiss franc strengthens
U.S. futures point to a modestly higher open as Middle East tensions ease slightly. Swiss Market Index climbs 0.2% on Roche and Logitech gains, while the franc strengthens after Swiss inflation surprises.
US stocks cautious as oil prices rise; Swiss franc strengthens on inflation data
Dow Jones and Nasdaq futures show muted gains ahead of key U.S. jobs data, while rising oil prices and geopolitical tensions curb risk appetite. Swiss franc surges to 0.9392 per euro after unexpected inflation jump.
Swiss Market Index falls 1.1% as heavyweights weigh on SMI
Partners Group gains 2.2%, Gurit surges 14% while Nestlé, Novartis and Roche decline. US tech rally lifts Nasdaq 100 to 29,518 as Nvidia, Salesforce and CrowdStrike advance.
Swiss shares rise as defensive stocks lead; gold rallies on softer jobs data
Swiss Market Index edges higher as Roche and other defensive stocks gain; gold jumps 0.63% on dovish US jobs report and weaker dollar. US semiconductor and software stocks diverge in premarket trading.
US stocks fluctuate as tech gains offset losses; SMI pares declines
Dow futures edge higher while Nasdaq 100 slips; energy price surge fuels inflation concerns ahead of Fed decision. Swiss market pares losses with defensive stocks leading gains.
Swiss stocks slip as oil, rate fears weigh on markets
SMI falls 0.4% as Brent crude tops $95, inflation and ECB/Fed policy expectations drive defensive rotation; Roche, Swiss Life gain while Amrize, Holcim lag.
Nvidia lifts premarket U.S. stocks; Salesforce surges on outlook; SMI falls
U.S. futures rise as Nvidia’s results fuel AI optimism; Salesforce jumps 10% on raised revenue guidance. Swiss SMI declines 0.9% as heavyweights Nestlé, Novartis and Roche weigh.
Novartis shares hit record high on multiple sclerosis drug data
Swiss pharma giant rallies 6.3% after positive late-stage trial results for oral multiple sclerosis drug Remibrutinib, outpacing broader market slump. Analysts flag upside potential but warn of near-term consolidation risks.